A Class Act in Glaucoma Management: Differentiating Rho Kinase Inhibitors From the Pack
This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.
Activity Description
Medical management of glaucoma primarily focuses on lowering intraocular pressure (IOP) by decreasing aqueous production, reducing episcleral venous pressure, and/or increasing uveoscleral and trabecular outflow. Recently approved agents have expanded treatment options beyond the traditional mainstays of prostaglandin analogues and β-blockers, engaging Rho kinase (ROCK) inhibition to improve outcomes for patients with glaucoma. In this CE monograph, experts in the field will review the clinical and real-world data on ROCK inhibitor–based regimens for glaucoma, comparing monotherapy and combination therapy approaches for lowering IOP. Faculty will discuss the use of ROCK inhibitors to achieve individualized patient-specific treatment goals and review a clinical case to provide additional context for applying these therapies in practice.
Target Audience
The intended audience for this activity is comprehensive ophthalmologists and other healthcare professionals involved in the management of patients with glaucoma.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Differentiate the mechanism of action of Rho kinase inhibitors from other therapeutic classes of agents used in the treatment of glaucoma.
- Compare the use of Rho kinase inhibitor monotherapy versus combination therapy to lower intraocular pressure through all known mechanisms.
Activity Chair
Jason Bacharach, MD
Founding Partner and Director of Clinical Research
North Bay Eye Associates, Inc.
Co-Director, Glaucoma Division
California Pacific Medical Center
San Francisco, CA
Faculty
Inder Paul Singh, MD
President and Head of the Division of Glaucoma and Research
Eye Centers of Racine and Kenosha
Racine, WI
Sarah H. Van Tassel, MD
Director, Glaucoma Service
Director, Glaucoma Fellowship
Assistant Professor of Ophthalmology
Weill Cornell Medicine
New York, NY
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Medical Writer
Valerie Zimmerman, PhD
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, May 25, 2023, to May 25, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of the 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Bacharach, Singh, and Van Tassel during a live/virtual expert panel discussion/satellite symposium held on January 18, 2023. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Jason Bacharach, MD
Advisor: Aerie, Bausch + Lomb, Eyevance, Glaukos, Humphrey-Zeiss, Imprimis, Injectsense, Iridex, New World Medical, Ocular Therapeutix, Santen, Topcon
Consultant: Aerie, Bausch + Lomb, Eyevance, Glaukos, Humphrey-Zeiss, Imprimis, Injectsense, Iridex, New World Medical, Ocular Therapeutix, Santen, Topcon
Speaker Contracted by Ineligible Company: Aerie, Bausch + Lomb, Iridex, Sun
Independent Research Contractor: Elios, Glaukos, Nicox, Ocular Therapeutix, Oculis, Oculus, Ocuphire, Ora, Santen, Sight Science, Sun, TearClear, Topcon
Individual Stocks and Stock Options: Injectsense
Inder Paul Singh, MD
Advisor: Imprimus, Ocuphire
Consultant: Alcon, Bausch + Lomb, Elios Vision, iSTAR, New World Medical, Ocular Therapeutix, Sight Sciences, VISIOX, Zeiss
Speaker Contracted by Ineligible Company: Alcon, Bausch + Lomb, New World Medical, Ocular Therapeutix, Sight Sciences, Zeiss
Sarah H. Van Tassel, MD
Consultant: Aerie, Alcon, Bausch + Lomb, BELKIN Vision, Glaukos, New World Medical, Thea, Zeiss
Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Medical Writer reports the following relevant financial relationship(s)
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com